STL Index for: Mohamad R. Taha

Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.

Learn about the role of biofilms in skin disorders like acne, atopic dermatitis, and chronic wounds. This article explores how biofilms contribute to disease pathogenesis, their resistance to antibiotics, and the latest conventional and innovative treatments aimed at targeting biofilm-associated skin conditions.